Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
6,367
archived clinical trials in
High Blood Pressure (Hypertension)

Clinical Study to Assess the Long-term Safety and Tolerability of ACT 064992 in Patients With Symptomatic Pulmonary Arterial Hypertension
Long-term Single-arm Open-label Extension Study of the SERAPHIN Study, to Assess the Safety and Tolerability of ACT 064992 in Patients With Symptomatic Pulmonary Arterial Hypertension
Status: Enrolling
Updated:  12/31/1969
Arizona Pulmonary Specialists, Ltd.
342
mi
from 91732
Phoenix, AZ
Clinical Study to Assess the Long-term Safety and Tolerability of ACT 064992 in Patients With Symptomatic Pulmonary Arterial Hypertension
Long-term Single-arm Open-label Extension Study of the SERAPHIN Study, to Assess the Safety and Tolerability of ACT 064992 in Patients With Symptomatic Pulmonary Arterial Hypertension
Status: Enrolling
Updated: 12/31/1969
Arizona Pulmonary Specialists, Ltd.
342
mi
from 91732
Phoenix, AZ
Click here to add this to my saved trials
Clinical Study to Assess the Long-term Safety and Tolerability of ACT 064992 in Patients With Symptomatic Pulmonary Arterial Hypertension
Long-term Single-arm Open-label Extension Study of the SERAPHIN Study, to Assess the Safety and Tolerability of ACT 064992 in Patients With Symptomatic Pulmonary Arterial Hypertension
Status: Enrolling
Updated:  12/31/1969
GLVA Healthcare Center
mi
from 91732
Los Angeles, CA
Clinical Study to Assess the Long-term Safety and Tolerability of ACT 064992 in Patients With Symptomatic Pulmonary Arterial Hypertension
Long-term Single-arm Open-label Extension Study of the SERAPHIN Study, to Assess the Safety and Tolerability of ACT 064992 in Patients With Symptomatic Pulmonary Arterial Hypertension
Status: Enrolling
Updated: 12/31/1969
GLVA Healthcare Center
mi
from 91732
Los Angeles, CA
Click here to add this to my saved trials
Clinical Study to Assess the Long-term Safety and Tolerability of ACT 064992 in Patients With Symptomatic Pulmonary Arterial Hypertension
Long-term Single-arm Open-label Extension Study of the SERAPHIN Study, to Assess the Safety and Tolerability of ACT 064992 in Patients With Symptomatic Pulmonary Arterial Hypertension
Status: Enrolling
Updated:  12/31/1969
Santa Barbara Cottage Hospital
102
mi
from 91732
Santa Barbara, CA
Clinical Study to Assess the Long-term Safety and Tolerability of ACT 064992 in Patients With Symptomatic Pulmonary Arterial Hypertension
Long-term Single-arm Open-label Extension Study of the SERAPHIN Study, to Assess the Safety and Tolerability of ACT 064992 in Patients With Symptomatic Pulmonary Arterial Hypertension
Status: Enrolling
Updated: 12/31/1969
Santa Barbara Cottage Hospital
102
mi
from 91732
Santa Barbara, CA
Click here to add this to my saved trials
Clinical Study to Assess the Long-term Safety and Tolerability of ACT 064992 in Patients With Symptomatic Pulmonary Arterial Hypertension
Long-term Single-arm Open-label Extension Study of the SERAPHIN Study, to Assess the Safety and Tolerability of ACT 064992 in Patients With Symptomatic Pulmonary Arterial Hypertension
Status: Enrolling
Updated:  12/31/1969
LIU Center for Pulmonary Hypertension
24
mi
from 91732
Torrance, CA
Clinical Study to Assess the Long-term Safety and Tolerability of ACT 064992 in Patients With Symptomatic Pulmonary Arterial Hypertension
Long-term Single-arm Open-label Extension Study of the SERAPHIN Study, to Assess the Safety and Tolerability of ACT 064992 in Patients With Symptomatic Pulmonary Arterial Hypertension
Status: Enrolling
Updated: 12/31/1969
LIU Center for Pulmonary Hypertension
24
mi
from 91732
Torrance, CA
Click here to add this to my saved trials
Clinical Study to Assess the Long-term Safety and Tolerability of ACT 064992 in Patients With Symptomatic Pulmonary Arterial Hypertension
Long-term Single-arm Open-label Extension Study of the SERAPHIN Study, to Assess the Safety and Tolerability of ACT 064992 in Patients With Symptomatic Pulmonary Arterial Hypertension
Status: Enrolling
Updated:  12/31/1969
Mayo Clinic, Jacksonville
2135
mi
from 91732
Jacksonville, FL
Clinical Study to Assess the Long-term Safety and Tolerability of ACT 064992 in Patients With Symptomatic Pulmonary Arterial Hypertension
Long-term Single-arm Open-label Extension Study of the SERAPHIN Study, to Assess the Safety and Tolerability of ACT 064992 in Patients With Symptomatic Pulmonary Arterial Hypertension
Status: Enrolling
Updated: 12/31/1969
Mayo Clinic, Jacksonville
2135
mi
from 91732
Jacksonville, FL
Click here to add this to my saved trials
Clinical Study to Assess the Long-term Safety and Tolerability of ACT 064992 in Patients With Symptomatic Pulmonary Arterial Hypertension
Long-term Single-arm Open-label Extension Study of the SERAPHIN Study, to Assess the Safety and Tolerability of ACT 064992 in Patients With Symptomatic Pulmonary Arterial Hypertension
Status: Enrolling
Updated:  12/31/1969
Emory University Hospital - McKelvey Center for Lung Transplantation & Pulmonary Vascular Disease
1919
mi
from 91732
Atlanta, GA
Clinical Study to Assess the Long-term Safety and Tolerability of ACT 064992 in Patients With Symptomatic Pulmonary Arterial Hypertension
Long-term Single-arm Open-label Extension Study of the SERAPHIN Study, to Assess the Safety and Tolerability of ACT 064992 in Patients With Symptomatic Pulmonary Arterial Hypertension
Status: Enrolling
Updated: 12/31/1969
Emory University Hospital - McKelvey Center for Lung Transplantation & Pulmonary Vascular Disease
1919
mi
from 91732
Atlanta, GA
Click here to add this to my saved trials
Clinical Study to Assess the Long-term Safety and Tolerability of ACT 064992 in Patients With Symptomatic Pulmonary Arterial Hypertension
Long-term Single-arm Open-label Extension Study of the SERAPHIN Study, to Assess the Safety and Tolerability of ACT 064992 in Patients With Symptomatic Pulmonary Arterial Hypertension
Status: Enrolling
Updated:  12/31/1969
Pulmonary & Critical Care of Atlanta
1918
mi
from 91732
Atlanta, GA
Clinical Study to Assess the Long-term Safety and Tolerability of ACT 064992 in Patients With Symptomatic Pulmonary Arterial Hypertension
Long-term Single-arm Open-label Extension Study of the SERAPHIN Study, to Assess the Safety and Tolerability of ACT 064992 in Patients With Symptomatic Pulmonary Arterial Hypertension
Status: Enrolling
Updated: 12/31/1969
Pulmonary & Critical Care of Atlanta
1918
mi
from 91732
Atlanta, GA
Click here to add this to my saved trials
Clinical Study to Assess the Long-term Safety and Tolerability of ACT 064992 in Patients With Symptomatic Pulmonary Arterial Hypertension
Long-term Single-arm Open-label Extension Study of the SERAPHIN Study, to Assess the Safety and Tolerability of ACT 064992 in Patients With Symptomatic Pulmonary Arterial Hypertension
Status: Enrolling
Updated:  12/31/1969
University of Chicago
1730
mi
from 91732
Chicago, IL
Clinical Study to Assess the Long-term Safety and Tolerability of ACT 064992 in Patients With Symptomatic Pulmonary Arterial Hypertension
Long-term Single-arm Open-label Extension Study of the SERAPHIN Study, to Assess the Safety and Tolerability of ACT 064992 in Patients With Symptomatic Pulmonary Arterial Hypertension
Status: Enrolling
Updated: 12/31/1969
University of Chicago
1730
mi
from 91732
Chicago, IL
Click here to add this to my saved trials
Clinical Study to Assess the Long-term Safety and Tolerability of ACT 064992 in Patients With Symptomatic Pulmonary Arterial Hypertension
Long-term Single-arm Open-label Extension Study of the SERAPHIN Study, to Assess the Safety and Tolerability of ACT 064992 in Patients With Symptomatic Pulmonary Arterial Hypertension
Status: Enrolling
Updated:  12/31/1969
University of Iowa Pulmonary Hypertension Program
1528
mi
from 91732
Iowa City, IA
Clinical Study to Assess the Long-term Safety and Tolerability of ACT 064992 in Patients With Symptomatic Pulmonary Arterial Hypertension
Long-term Single-arm Open-label Extension Study of the SERAPHIN Study, to Assess the Safety and Tolerability of ACT 064992 in Patients With Symptomatic Pulmonary Arterial Hypertension
Status: Enrolling
Updated: 12/31/1969
University of Iowa Pulmonary Hypertension Program
1528
mi
from 91732
Iowa City, IA
Click here to add this to my saved trials
Clinical Study to Assess the Long-term Safety and Tolerability of ACT 064992 in Patients With Symptomatic Pulmonary Arterial Hypertension
Long-term Single-arm Open-label Extension Study of the SERAPHIN Study, to Assess the Safety and Tolerability of ACT 064992 in Patients With Symptomatic Pulmonary Arterial Hypertension
Status: Enrolling
Updated:  12/31/1969
University of Kansas Medical Center
1332
mi
from 91732
Kansas City, KA
Clinical Study to Assess the Long-term Safety and Tolerability of ACT 064992 in Patients With Symptomatic Pulmonary Arterial Hypertension
Long-term Single-arm Open-label Extension Study of the SERAPHIN Study, to Assess the Safety and Tolerability of ACT 064992 in Patients With Symptomatic Pulmonary Arterial Hypertension
Status: Enrolling
Updated: 12/31/1969
University of Kansas Medical Center
1332
mi
from 91732
Kansas City, KA
Click here to add this to my saved trials
Clinical Study to Assess the Long-term Safety and Tolerability of ACT 064992 in Patients With Symptomatic Pulmonary Arterial Hypertension
Long-term Single-arm Open-label Extension Study of the SERAPHIN Study, to Assess the Safety and Tolerability of ACT 064992 in Patients With Symptomatic Pulmonary Arterial Hypertension
Status: Enrolling
Updated:  12/31/1969
Kentuckiana Pulmonary Associate, PLLC
1812
mi
from 91732
Louisville, KY
Clinical Study to Assess the Long-term Safety and Tolerability of ACT 064992 in Patients With Symptomatic Pulmonary Arterial Hypertension
Long-term Single-arm Open-label Extension Study of the SERAPHIN Study, to Assess the Safety and Tolerability of ACT 064992 in Patients With Symptomatic Pulmonary Arterial Hypertension
Status: Enrolling
Updated: 12/31/1969
Kentuckiana Pulmonary Associate, PLLC
1812
mi
from 91732
Louisville, KY
Click here to add this to my saved trials
Clinical Study to Assess the Long-term Safety and Tolerability of ACT 064992 in Patients With Symptomatic Pulmonary Arterial Hypertension
Long-term Single-arm Open-label Extension Study of the SERAPHIN Study, to Assess the Safety and Tolerability of ACT 064992 in Patients With Symptomatic Pulmonary Arterial Hypertension
Status: Enrolling
Updated:  12/31/1969
Maine Medical Center
2614
mi
from 91732
Portland, ME
Clinical Study to Assess the Long-term Safety and Tolerability of ACT 064992 in Patients With Symptomatic Pulmonary Arterial Hypertension
Long-term Single-arm Open-label Extension Study of the SERAPHIN Study, to Assess the Safety and Tolerability of ACT 064992 in Patients With Symptomatic Pulmonary Arterial Hypertension
Status: Enrolling
Updated: 12/31/1969
Maine Medical Center
2614
mi
from 91732
Portland, ME
Click here to add this to my saved trials
Clinical Study to Assess the Long-term Safety and Tolerability of ACT 064992 in Patients With Symptomatic Pulmonary Arterial Hypertension
Long-term Single-arm Open-label Extension Study of the SERAPHIN Study, to Assess the Safety and Tolerability of ACT 064992 in Patients With Symptomatic Pulmonary Arterial Hypertension
Status: Enrolling
Updated:  12/31/1969
University of Maryland School of Medicine; Division of Cardiology
2301
mi
from 91732
Baltimore, MD
Clinical Study to Assess the Long-term Safety and Tolerability of ACT 064992 in Patients With Symptomatic Pulmonary Arterial Hypertension
Long-term Single-arm Open-label Extension Study of the SERAPHIN Study, to Assess the Safety and Tolerability of ACT 064992 in Patients With Symptomatic Pulmonary Arterial Hypertension
Status: Enrolling
Updated: 12/31/1969
University of Maryland School of Medicine; Division of Cardiology
2301
mi
from 91732
Baltimore, MD
Click here to add this to my saved trials
Clinical Study to Assess the Long-term Safety and Tolerability of ACT 064992 in Patients With Symptomatic Pulmonary Arterial Hypertension
Long-term Single-arm Open-label Extension Study of the SERAPHIN Study, to Assess the Safety and Tolerability of ACT 064992 in Patients With Symptomatic Pulmonary Arterial Hypertension
Status: Enrolling
Updated:  12/31/1969
Pulmonary/Critical Care Division/Tufts New England Medical Center
2578
mi
from 91732
Boston, MA
Clinical Study to Assess the Long-term Safety and Tolerability of ACT 064992 in Patients With Symptomatic Pulmonary Arterial Hypertension
Long-term Single-arm Open-label Extension Study of the SERAPHIN Study, to Assess the Safety and Tolerability of ACT 064992 in Patients With Symptomatic Pulmonary Arterial Hypertension
Status: Enrolling
Updated: 12/31/1969
Pulmonary/Critical Care Division/Tufts New England Medical Center
2578
mi
from 91732
Boston, MA
Click here to add this to my saved trials
Clinical Study to Assess the Long-term Safety and Tolerability of ACT 064992 in Patients With Symptomatic Pulmonary Arterial Hypertension
Long-term Single-arm Open-label Extension Study of the SERAPHIN Study, to Assess the Safety and Tolerability of ACT 064992 in Patients With Symptomatic Pulmonary Arterial Hypertension
Status: Enrolling
Updated:  12/31/1969
Boston University School of Medicine
2577
mi
from 91732
Boston, MA
Clinical Study to Assess the Long-term Safety and Tolerability of ACT 064992 in Patients With Symptomatic Pulmonary Arterial Hypertension
Long-term Single-arm Open-label Extension Study of the SERAPHIN Study, to Assess the Safety and Tolerability of ACT 064992 in Patients With Symptomatic Pulmonary Arterial Hypertension
Status: Enrolling
Updated: 12/31/1969
Boston University School of Medicine
2577
mi
from 91732
Boston, MA
Click here to add this to my saved trials
Clinical Study to Assess the Long-term Safety and Tolerability of ACT 064992 in Patients With Symptomatic Pulmonary Arterial Hypertension
Long-term Single-arm Open-label Extension Study of the SERAPHIN Study, to Assess the Safety and Tolerability of ACT 064992 in Patients With Symptomatic Pulmonary Arterial Hypertension
Status: Enrolling
Updated:  12/31/1969
University of Michigan
1932
mi
from 91732
Ann Arbor, MI
Clinical Study to Assess the Long-term Safety and Tolerability of ACT 064992 in Patients With Symptomatic Pulmonary Arterial Hypertension
Long-term Single-arm Open-label Extension Study of the SERAPHIN Study, to Assess the Safety and Tolerability of ACT 064992 in Patients With Symptomatic Pulmonary Arterial Hypertension
Status: Enrolling
Updated: 12/31/1969
University of Michigan
1932
mi
from 91732
Ann Arbor, MI
Click here to add this to my saved trials
Clinical Study to Assess the Long-term Safety and Tolerability of ACT 064992 in Patients With Symptomatic Pulmonary Arterial Hypertension
Long-term Single-arm Open-label Extension Study of the SERAPHIN Study, to Assess the Safety and Tolerability of ACT 064992 in Patients With Symptomatic Pulmonary Arterial Hypertension
Status: Enrolling
Updated:  12/31/1969
Columbia University Medical Center, Pediatric Cardiology
2435
mi
from 91732
New York, NY
Clinical Study to Assess the Long-term Safety and Tolerability of ACT 064992 in Patients With Symptomatic Pulmonary Arterial Hypertension
Long-term Single-arm Open-label Extension Study of the SERAPHIN Study, to Assess the Safety and Tolerability of ACT 064992 in Patients With Symptomatic Pulmonary Arterial Hypertension
Status: Enrolling
Updated: 12/31/1969
Columbia University Medical Center, Pediatric Cardiology
2435
mi
from 91732
New York, NY
Click here to add this to my saved trials
Clinical Study to Assess the Long-term Safety and Tolerability of ACT 064992 in Patients With Symptomatic Pulmonary Arterial Hypertension
Long-term Single-arm Open-label Extension Study of the SERAPHIN Study, to Assess the Safety and Tolerability of ACT 064992 in Patients With Symptomatic Pulmonary Arterial Hypertension
Status: Enrolling
Updated:  12/31/1969
Ohio State University, Div. of Pul. & Critical Care
1959
mi
from 91732
Columbus, OH
Clinical Study to Assess the Long-term Safety and Tolerability of ACT 064992 in Patients With Symptomatic Pulmonary Arterial Hypertension
Long-term Single-arm Open-label Extension Study of the SERAPHIN Study, to Assess the Safety and Tolerability of ACT 064992 in Patients With Symptomatic Pulmonary Arterial Hypertension
Status: Enrolling
Updated: 12/31/1969
Ohio State University, Div. of Pul. & Critical Care
1959
mi
from 91732
Columbus, OH
Click here to add this to my saved trials
Clinical Study to Assess the Long-term Safety and Tolerability of ACT 064992 in Patients With Symptomatic Pulmonary Arterial Hypertension
Long-term Single-arm Open-label Extension Study of the SERAPHIN Study, to Assess the Safety and Tolerability of ACT 064992 in Patients With Symptomatic Pulmonary Arterial Hypertension
Status: Enrolling
Updated:  12/31/1969
University of Texas Medical Center - St. Paul University
1223
mi
from 91732
Dallas, TX
Clinical Study to Assess the Long-term Safety and Tolerability of ACT 064992 in Patients With Symptomatic Pulmonary Arterial Hypertension
Long-term Single-arm Open-label Extension Study of the SERAPHIN Study, to Assess the Safety and Tolerability of ACT 064992 in Patients With Symptomatic Pulmonary Arterial Hypertension
Status: Enrolling
Updated: 12/31/1969
University of Texas Medical Center - St. Paul University
1223
mi
from 91732
Dallas, TX
Click here to add this to my saved trials
Clinical Study to Assess the Long-term Safety and Tolerability of ACT 064992 in Patients With Symptomatic Pulmonary Arterial Hypertension
Long-term Single-arm Open-label Extension Study of the SERAPHIN Study, to Assess the Safety and Tolerability of ACT 064992 in Patients With Symptomatic Pulmonary Arterial Hypertension
Status: Enrolling
Updated:  12/31/1969
Baylor College of Medicine/The Methodist Hospital
1357
mi
from 91732
Houston, TX
Clinical Study to Assess the Long-term Safety and Tolerability of ACT 064992 in Patients With Symptomatic Pulmonary Arterial Hypertension
Long-term Single-arm Open-label Extension Study of the SERAPHIN Study, to Assess the Safety and Tolerability of ACT 064992 in Patients With Symptomatic Pulmonary Arterial Hypertension
Status: Enrolling
Updated: 12/31/1969
Baylor College of Medicine/The Methodist Hospital
1357
mi
from 91732
Houston, TX
Click here to add this to my saved trials
Clinical Study to Assess the Long-term Safety and Tolerability of ACT 064992 in Patients With Symptomatic Pulmonary Arterial Hypertension
Long-term Single-arm Open-label Extension Study of the SERAPHIN Study, to Assess the Safety and Tolerability of ACT 064992 in Patients With Symptomatic Pulmonary Arterial Hypertension
Status: Enrolling
Updated:  12/31/1969
Sentara Hospitals T/A Sentara Cardiovascular Research Intitute
2336
mi
from 91732
Norfolk, VA
Clinical Study to Assess the Long-term Safety and Tolerability of ACT 064992 in Patients With Symptomatic Pulmonary Arterial Hypertension
Long-term Single-arm Open-label Extension Study of the SERAPHIN Study, to Assess the Safety and Tolerability of ACT 064992 in Patients With Symptomatic Pulmonary Arterial Hypertension
Status: Enrolling
Updated: 12/31/1969
Sentara Hospitals T/A Sentara Cardiovascular Research Intitute
2336
mi
from 91732
Norfolk, VA
Click here to add this to my saved trials
Clinical Study to Assess the Long-term Safety and Tolerability of ACT 064992 in Patients With Symptomatic Pulmonary Arterial Hypertension
Long-term Single-arm Open-label Extension Study of the SERAPHIN Study, to Assess the Safety and Tolerability of ACT 064992 in Patients With Symptomatic Pulmonary Arterial Hypertension
Status: Enrolling
Updated:  12/31/1969
Sanatorio Otamendi y Miroli S.A.
mi
from 91732
Buenos Aires,
Clinical Study to Assess the Long-term Safety and Tolerability of ACT 064992 in Patients With Symptomatic Pulmonary Arterial Hypertension
Long-term Single-arm Open-label Extension Study of the SERAPHIN Study, to Assess the Safety and Tolerability of ACT 064992 in Patients With Symptomatic Pulmonary Arterial Hypertension
Status: Enrolling
Updated: 12/31/1969
Sanatorio Otamendi y Miroli S.A.
mi
from 91732
Buenos Aires,
Click here to add this to my saved trials
Clinical Study to Assess the Long-term Safety and Tolerability of ACT 064992 in Patients With Symptomatic Pulmonary Arterial Hypertension
Long-term Single-arm Open-label Extension Study of the SERAPHIN Study, to Assess the Safety and Tolerability of ACT 064992 in Patients With Symptomatic Pulmonary Arterial Hypertension
Status: Enrolling
Updated:  12/31/1969
Atlanta Institute for Medical Research, Inc
1924
mi
from 91732
Decatur, GA
Clinical Study to Assess the Long-term Safety and Tolerability of ACT 064992 in Patients With Symptomatic Pulmonary Arterial Hypertension
Long-term Single-arm Open-label Extension Study of the SERAPHIN Study, to Assess the Safety and Tolerability of ACT 064992 in Patients With Symptomatic Pulmonary Arterial Hypertension
Status: Enrolling
Updated: 12/31/1969
Atlanta Institute for Medical Research, Inc
1924
mi
from 91732
Decatur, GA
Click here to add this to my saved trials
Clinical Study to Assess the Long-term Safety and Tolerability of ACT 064992 in Patients With Symptomatic Pulmonary Arterial Hypertension
Long-term Single-arm Open-label Extension Study of the SERAPHIN Study, to Assess the Safety and Tolerability of ACT 064992 in Patients With Symptomatic Pulmonary Arterial Hypertension
Status: Enrolling
Updated:  12/31/1969
Louisiana State University Health Sciences Center
1655
mi
from 91732
New Orleans, LA
Clinical Study to Assess the Long-term Safety and Tolerability of ACT 064992 in Patients With Symptomatic Pulmonary Arterial Hypertension
Long-term Single-arm Open-label Extension Study of the SERAPHIN Study, to Assess the Safety and Tolerability of ACT 064992 in Patients With Symptomatic Pulmonary Arterial Hypertension
Status: Enrolling
Updated: 12/31/1969
Louisiana State University Health Sciences Center
1655
mi
from 91732
New Orleans, LA
Click here to add this to my saved trials
Clinical Study to Assess the Long-term Safety and Tolerability of ACT 064992 in Patients With Symptomatic Pulmonary Arterial Hypertension
Long-term Single-arm Open-label Extension Study of the SERAPHIN Study, to Assess the Safety and Tolerability of ACT 064992 in Patients With Symptomatic Pulmonary Arterial Hypertension
Status: Enrolling
Updated:  12/31/1969
Aurora St. Luke's Medical Center
1726
mi
from 91732
Milwaukee, WI
Clinical Study to Assess the Long-term Safety and Tolerability of ACT 064992 in Patients With Symptomatic Pulmonary Arterial Hypertension
Long-term Single-arm Open-label Extension Study of the SERAPHIN Study, to Assess the Safety and Tolerability of ACT 064992 in Patients With Symptomatic Pulmonary Arterial Hypertension
Status: Enrolling
Updated: 12/31/1969
Aurora St. Luke's Medical Center
1726
mi
from 91732
Milwaukee, WI
Click here to add this to my saved trials
Clinical Study to Assess the Long-term Safety and Tolerability of ACT 064992 in Patients With Symptomatic Pulmonary Arterial Hypertension
Long-term Single-arm Open-label Extension Study of the SERAPHIN Study, to Assess the Safety and Tolerability of ACT 064992 in Patients With Symptomatic Pulmonary Arterial Hypertension
Status: Enrolling
Updated:  12/31/1969
Washington University School of Medicine
1569
mi
from 91732
Saint Louis, MO
Clinical Study to Assess the Long-term Safety and Tolerability of ACT 064992 in Patients With Symptomatic Pulmonary Arterial Hypertension
Long-term Single-arm Open-label Extension Study of the SERAPHIN Study, to Assess the Safety and Tolerability of ACT 064992 in Patients With Symptomatic Pulmonary Arterial Hypertension
Status: Enrolling
Updated: 12/31/1969
Washington University School of Medicine
1569
mi
from 91732
Saint Louis, MO
Click here to add this to my saved trials
Clinical Study to Assess the Long-term Safety and Tolerability of ACT 064992 in Patients With Symptomatic Pulmonary Arterial Hypertension
Long-term Single-arm Open-label Extension Study of the SERAPHIN Study, to Assess the Safety and Tolerability of ACT 064992 in Patients With Symptomatic Pulmonary Arterial Hypertension
Status: Enrolling
Updated:  12/31/1969
The University of California, San Diego
95
mi
from 91732
La Jolla, CA
Clinical Study to Assess the Long-term Safety and Tolerability of ACT 064992 in Patients With Symptomatic Pulmonary Arterial Hypertension
Long-term Single-arm Open-label Extension Study of the SERAPHIN Study, to Assess the Safety and Tolerability of ACT 064992 in Patients With Symptomatic Pulmonary Arterial Hypertension
Status: Enrolling
Updated: 12/31/1969
The University of California, San Diego
95
mi
from 91732
La Jolla, CA
Click here to add this to my saved trials
Clinical Study to Assess the Long-term Safety and Tolerability of ACT 064992 in Patients With Symptomatic Pulmonary Arterial Hypertension
Long-term Single-arm Open-label Extension Study of the SERAPHIN Study, to Assess the Safety and Tolerability of ACT 064992 in Patients With Symptomatic Pulmonary Arterial Hypertension
Status: Enrolling
Updated:  12/31/1969
University of Colorado Cardiac and Vascular Center
825
mi
from 91732
Aurora, CO
Clinical Study to Assess the Long-term Safety and Tolerability of ACT 064992 in Patients With Symptomatic Pulmonary Arterial Hypertension
Long-term Single-arm Open-label Extension Study of the SERAPHIN Study, to Assess the Safety and Tolerability of ACT 064992 in Patients With Symptomatic Pulmonary Arterial Hypertension
Status: Enrolling
Updated: 12/31/1969
University of Colorado Cardiac and Vascular Center
825
mi
from 91732
Aurora, CO
Click here to add this to my saved trials
Clinical Study to Assess the Long-term Safety and Tolerability of ACT 064992 in Patients With Symptomatic Pulmonary Arterial Hypertension
Long-term Single-arm Open-label Extension Study of the SERAPHIN Study, to Assess the Safety and Tolerability of ACT 064992 in Patients With Symptomatic Pulmonary Arterial Hypertension
Status: Enrolling
Updated:  12/31/1969
Intermountain Med Ctr- Pulm Dept Heart and Lung Ctr
mi
from 91732
Murray, UT
Clinical Study to Assess the Long-term Safety and Tolerability of ACT 064992 in Patients With Symptomatic Pulmonary Arterial Hypertension
Long-term Single-arm Open-label Extension Study of the SERAPHIN Study, to Assess the Safety and Tolerability of ACT 064992 in Patients With Symptomatic Pulmonary Arterial Hypertension
Status: Enrolling
Updated: 12/31/1969
Intermountain Med Ctr- Pulm Dept Heart and Lung Ctr
mi
from 91732
Murray, UT
Click here to add this to my saved trials
Study of Ambrisentan in Subjects With Pulmonary Hypertension
ABS-LT: A Phase 3, Long-Term, Open Label, Multicenter Safety Study of Ambrisentan in Subjects With Pulmonary Hypertension
Status: Enrolling
Updated:  12/31/1969
University of Alabama at Birmingham
1777
mi
from 91732
Birmingham, AL
Study of Ambrisentan in Subjects With Pulmonary Hypertension
ABS-LT: A Phase 3, Long-Term, Open Label, Multicenter Safety Study of Ambrisentan in Subjects With Pulmonary Hypertension
Status: Enrolling
Updated: 12/31/1969
University of Alabama at Birmingham
1777
mi
from 91732
Birmingham, AL
Click here to add this to my saved trials
Study of Ambrisentan in Subjects With Pulmonary Hypertension
ABS-LT: A Phase 3, Long-Term, Open Label, Multicenter Safety Study of Ambrisentan in Subjects With Pulmonary Hypertension
Status: Enrolling
Updated:  12/31/1969
Arizona Pulmonary Specialists, Ltd.
342
mi
from 91732
Phoenix, AZ
Study of Ambrisentan in Subjects With Pulmonary Hypertension
ABS-LT: A Phase 3, Long-Term, Open Label, Multicenter Safety Study of Ambrisentan in Subjects With Pulmonary Hypertension
Status: Enrolling
Updated: 12/31/1969
Arizona Pulmonary Specialists, Ltd.
342
mi
from 91732
Phoenix, AZ
Click here to add this to my saved trials
Study of Ambrisentan in Subjects With Pulmonary Hypertension
ABS-LT: A Phase 3, Long-Term, Open Label, Multicenter Safety Study of Ambrisentan in Subjects With Pulmonary Hypertension
Status: Enrolling
Updated:  12/31/1969
University of Colorado Health Science Center
825
mi
from 91732
Aurora, CO
Study of Ambrisentan in Subjects With Pulmonary Hypertension
ABS-LT: A Phase 3, Long-Term, Open Label, Multicenter Safety Study of Ambrisentan in Subjects With Pulmonary Hypertension
Status: Enrolling
Updated: 12/31/1969
University of Colorado Health Science Center
825
mi
from 91732
Aurora, CO
Click here to add this to my saved trials
Study of Ambrisentan in Subjects With Pulmonary Hypertension
ABS-LT: A Phase 3, Long-Term, Open Label, Multicenter Safety Study of Ambrisentan in Subjects With Pulmonary Hypertension
Status: Enrolling
Updated:  12/31/1969
University of Connecticut Health Center
2489
mi
from 91732
Farmington, CT
Study of Ambrisentan in Subjects With Pulmonary Hypertension
ABS-LT: A Phase 3, Long-Term, Open Label, Multicenter Safety Study of Ambrisentan in Subjects With Pulmonary Hypertension
Status: Enrolling
Updated: 12/31/1969
University of Connecticut Health Center
2489
mi
from 91732
Farmington, CT
Click here to add this to my saved trials
Study of Ambrisentan in Subjects With Pulmonary Hypertension
ABS-LT: A Phase 3, Long-Term, Open Label, Multicenter Safety Study of Ambrisentan in Subjects With Pulmonary Hypertension
Status: Enrolling
Updated:  12/31/1969
Atlanta Institute For Medical Research, Inc
1919
mi
from 91732
Atlanta, GA
Study of Ambrisentan in Subjects With Pulmonary Hypertension
ABS-LT: A Phase 3, Long-Term, Open Label, Multicenter Safety Study of Ambrisentan in Subjects With Pulmonary Hypertension
Status: Enrolling
Updated: 12/31/1969
Atlanta Institute For Medical Research, Inc
1919
mi
from 91732
Atlanta, GA
Click here to add this to my saved trials
Study of Ambrisentan in Subjects With Pulmonary Hypertension
ABS-LT: A Phase 3, Long-Term, Open Label, Multicenter Safety Study of Ambrisentan in Subjects With Pulmonary Hypertension
Status: Enrolling
Updated:  12/31/1969
University of Iowa
1527
mi
from 91732
Iowa City, IA
Study of Ambrisentan in Subjects With Pulmonary Hypertension
ABS-LT: A Phase 3, Long-Term, Open Label, Multicenter Safety Study of Ambrisentan in Subjects With Pulmonary Hypertension
Status: Enrolling
Updated: 12/31/1969
University of Iowa
1527
mi
from 91732
Iowa City, IA
Click here to add this to my saved trials
Study of Ambrisentan in Subjects With Pulmonary Hypertension
ABS-LT: A Phase 3, Long-Term, Open Label, Multicenter Safety Study of Ambrisentan in Subjects With Pulmonary Hypertension
Status: Enrolling
Updated:  12/31/1969
Tufts Medical Center
2578
mi
from 91732
Boston, MA
Study of Ambrisentan in Subjects With Pulmonary Hypertension
ABS-LT: A Phase 3, Long-Term, Open Label, Multicenter Safety Study of Ambrisentan in Subjects With Pulmonary Hypertension
Status: Enrolling
Updated: 12/31/1969
Tufts Medical Center
2578
mi
from 91732
Boston, MA
Click here to add this to my saved trials
Study of Ambrisentan in Subjects With Pulmonary Hypertension
ABS-LT: A Phase 3, Long-Term, Open Label, Multicenter Safety Study of Ambrisentan in Subjects With Pulmonary Hypertension
Status: Enrolling
Updated:  12/31/1969
BACH Cardiology/Children's Hospital
2576
mi
from 91732
Boston, MA
Study of Ambrisentan in Subjects With Pulmonary Hypertension
ABS-LT: A Phase 3, Long-Term, Open Label, Multicenter Safety Study of Ambrisentan in Subjects With Pulmonary Hypertension
Status: Enrolling
Updated: 12/31/1969
BACH Cardiology/Children's Hospital
2576
mi
from 91732
Boston, MA
Click here to add this to my saved trials
Study of Ambrisentan in Subjects With Pulmonary Hypertension
ABS-LT: A Phase 3, Long-Term, Open Label, Multicenter Safety Study of Ambrisentan in Subjects With Pulmonary Hypertension
Status: Enrolling
Updated:  12/31/1969
Brigham and Women's Hosp
2578
mi
from 91732
Boston, MA
Study of Ambrisentan in Subjects With Pulmonary Hypertension
ABS-LT: A Phase 3, Long-Term, Open Label, Multicenter Safety Study of Ambrisentan in Subjects With Pulmonary Hypertension
Status: Enrolling
Updated: 12/31/1969
Brigham and Women's Hosp
2578
mi
from 91732
Boston, MA
Click here to add this to my saved trials
Study of Ambrisentan in Subjects With Pulmonary Hypertension
ABS-LT: A Phase 3, Long-Term, Open Label, Multicenter Safety Study of Ambrisentan in Subjects With Pulmonary Hypertension
Status: Enrolling
Updated:  12/31/1969
Boston University Medical Center
2578
mi
from 91732
Boston, MA
Study of Ambrisentan in Subjects With Pulmonary Hypertension
ABS-LT: A Phase 3, Long-Term, Open Label, Multicenter Safety Study of Ambrisentan in Subjects With Pulmonary Hypertension
Status: Enrolling
Updated: 12/31/1969
Boston University Medical Center
2578
mi
from 91732
Boston, MA
Click here to add this to my saved trials
Study of Ambrisentan in Subjects With Pulmonary Hypertension
ABS-LT: A Phase 3, Long-Term, Open Label, Multicenter Safety Study of Ambrisentan in Subjects With Pulmonary Hypertension
Status: Enrolling
Updated:  12/31/1969
Newark Beth Israel Medical Center
2423
mi
from 91732
Newark, NJ
Study of Ambrisentan in Subjects With Pulmonary Hypertension
ABS-LT: A Phase 3, Long-Term, Open Label, Multicenter Safety Study of Ambrisentan in Subjects With Pulmonary Hypertension
Status: Enrolling
Updated: 12/31/1969
Newark Beth Israel Medical Center
2423
mi
from 91732
Newark, NJ
Click here to add this to my saved trials
Study of Ambrisentan in Subjects With Pulmonary Hypertension
ABS-LT: A Phase 3, Long-Term, Open Label, Multicenter Safety Study of Ambrisentan in Subjects With Pulmonary Hypertension
Status: Enrolling
Updated:  12/31/1969
Mary Parkes Asthma Center University of Rochester
2242
mi
from 91732
Rochester, NY
Study of Ambrisentan in Subjects With Pulmonary Hypertension
ABS-LT: A Phase 3, Long-Term, Open Label, Multicenter Safety Study of Ambrisentan in Subjects With Pulmonary Hypertension
Status: Enrolling
Updated: 12/31/1969
Mary Parkes Asthma Center University of Rochester
2242
mi
from 91732
Rochester, NY
Click here to add this to my saved trials
Study of Ambrisentan in Subjects With Pulmonary Hypertension
ABS-LT: A Phase 3, Long-Term, Open Label, Multicenter Safety Study of Ambrisentan in Subjects With Pulmonary Hypertension
Status: Enrolling
Updated:  12/31/1969
University of Pittsburgh Medical Center-Presbyterian
2119
mi
from 91732
Pittsburgh, PA
Study of Ambrisentan in Subjects With Pulmonary Hypertension
ABS-LT: A Phase 3, Long-Term, Open Label, Multicenter Safety Study of Ambrisentan in Subjects With Pulmonary Hypertension
Status: Enrolling
Updated: 12/31/1969
University of Pittsburgh Medical Center-Presbyterian
2119
mi
from 91732
Pittsburgh, PA
Click here to add this to my saved trials
Study of Ambrisentan in Subjects With Pulmonary Hypertension
ABS-LT: A Phase 3, Long-Term, Open Label, Multicenter Safety Study of Ambrisentan in Subjects With Pulmonary Hypertension
Status: Enrolling
Updated:  12/31/1969
Rhode Island Hospital
2562
mi
from 91732
Providence, RI
Study of Ambrisentan in Subjects With Pulmonary Hypertension
ABS-LT: A Phase 3, Long-Term, Open Label, Multicenter Safety Study of Ambrisentan in Subjects With Pulmonary Hypertension
Status: Enrolling
Updated: 12/31/1969
Rhode Island Hospital
2562
mi
from 91732
Providence, RI
Click here to add this to my saved trials
Study of Ambrisentan in Subjects With Pulmonary Hypertension
ABS-LT: A Phase 3, Long-Term, Open Label, Multicenter Safety Study of Ambrisentan in Subjects With Pulmonary Hypertension
Status: Enrolling
Updated:  12/31/1969
Lexington Pulmonary and Critical Care Medicine
2094
mi
from 91732
Lexington, SC
Study of Ambrisentan in Subjects With Pulmonary Hypertension
ABS-LT: A Phase 3, Long-Term, Open Label, Multicenter Safety Study of Ambrisentan in Subjects With Pulmonary Hypertension
Status: Enrolling
Updated: 12/31/1969
Lexington Pulmonary and Critical Care Medicine
2094
mi
from 91732
Lexington, SC
Click here to add this to my saved trials
Study of Ambrisentan in Subjects With Pulmonary Hypertension
ABS-LT: A Phase 3, Long-Term, Open Label, Multicenter Safety Study of Ambrisentan in Subjects With Pulmonary Hypertension
Status: Enrolling
Updated:  12/31/1969
Clinica Independencia Munro
6103
mi
from 91732
Buenos Aires,
Study of Ambrisentan in Subjects With Pulmonary Hypertension
ABS-LT: A Phase 3, Long-Term, Open Label, Multicenter Safety Study of Ambrisentan in Subjects With Pulmonary Hypertension
Status: Enrolling
Updated: 12/31/1969
Clinica Independencia Munro
6103
mi
from 91732
Buenos Aires,
Click here to add this to my saved trials
Study of Ambrisentan in Subjects With Pulmonary Hypertension
ABS-LT: A Phase 3, Long-Term, Open Label, Multicenter Safety Study of Ambrisentan in Subjects With Pulmonary Hypertension
Status: Enrolling
Updated:  12/31/1969
Washington University Medical Center
1570
mi
from 91732
Saint Louis, MO
Study of Ambrisentan in Subjects With Pulmonary Hypertension
ABS-LT: A Phase 3, Long-Term, Open Label, Multicenter Safety Study of Ambrisentan in Subjects With Pulmonary Hypertension
Status: Enrolling
Updated: 12/31/1969
Washington University Medical Center
1570
mi
from 91732
Saint Louis, MO
Click here to add this to my saved trials
BAY63-2521:Long-term Extension Study in Patients With Pulmonary Arterial Hypertension
Long-term Extension, Multicentre, Multi-national Study to Evaluate the Safety and Tolerability of Oral BAY63-2521 (1mg,1.5 mg, 2.0 mg, 2.5 mg Tid) in Patients With Symptomatic Pulmonary Arterial Hypertension (PAH)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
13
mi
from 91732
Los Angeles, CA
BAY63-2521:Long-term Extension Study in Patients With Pulmonary Arterial Hypertension
Long-term Extension, Multicentre, Multi-national Study to Evaluate the Safety and Tolerability of Oral BAY63-2521 (1mg,1.5 mg, 2.0 mg, 2.5 mg Tid) in Patients With Symptomatic Pulmonary Arterial Hypertension (PAH)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
13
mi
from 91732
Los Angeles, CA
Click here to add this to my saved trials
BAY63-2521:Long-term Extension Study in Patients With Pulmonary Arterial Hypertension
Long-term Extension, Multicentre, Multi-national Study to Evaluate the Safety and Tolerability of Oral BAY63-2521 (1mg,1.5 mg, 2.0 mg, 2.5 mg Tid) in Patients With Symptomatic Pulmonary Arterial Hypertension (PAH)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
364
mi
from 91732
Sacramento, CA
BAY63-2521:Long-term Extension Study in Patients With Pulmonary Arterial Hypertension
Long-term Extension, Multicentre, Multi-national Study to Evaluate the Safety and Tolerability of Oral BAY63-2521 (1mg,1.5 mg, 2.0 mg, 2.5 mg Tid) in Patients With Symptomatic Pulmonary Arterial Hypertension (PAH)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
364
mi
from 91732
Sacramento, CA
Click here to add this to my saved trials
BAY63-2521:Long-term Extension Study in Patients With Pulmonary Arterial Hypertension
Long-term Extension, Multicentre, Multi-national Study to Evaluate the Safety and Tolerability of Oral BAY63-2521 (1mg,1.5 mg, 2.0 mg, 2.5 mg Tid) in Patients With Symptomatic Pulmonary Arterial Hypertension (PAH)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
825
mi
from 91732
Aurora, CO
BAY63-2521:Long-term Extension Study in Patients With Pulmonary Arterial Hypertension
Long-term Extension, Multicentre, Multi-national Study to Evaluate the Safety and Tolerability of Oral BAY63-2521 (1mg,1.5 mg, 2.0 mg, 2.5 mg Tid) in Patients With Symptomatic Pulmonary Arterial Hypertension (PAH)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
825
mi
from 91732
Aurora, CO
Click here to add this to my saved trials
BAY63-2521:Long-term Extension Study in Patients With Pulmonary Arterial Hypertension
Long-term Extension, Multicentre, Multi-national Study to Evaluate the Safety and Tolerability of Oral BAY63-2521 (1mg,1.5 mg, 2.0 mg, 2.5 mg Tid) in Patients With Symptomatic Pulmonary Arterial Hypertension (PAH)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2578
mi
from 91732
Boston, MA
BAY63-2521:Long-term Extension Study in Patients With Pulmonary Arterial Hypertension
Long-term Extension, Multicentre, Multi-national Study to Evaluate the Safety and Tolerability of Oral BAY63-2521 (1mg,1.5 mg, 2.0 mg, 2.5 mg Tid) in Patients With Symptomatic Pulmonary Arterial Hypertension (PAH)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2578
mi
from 91732
Boston, MA
Click here to add this to my saved trials